Stocks
Avalyn Pharma Inc.AVLN
NASDAQHealthcareBiotechnology$24.63
Price as of · delayed, not real-time
A clinical-stage biopharmaceutical company developing inhaled therapies for respiratory diseases, including idiopathic pulmonary fibrosis. Its lead candidate, AV-101, targets a pathway distinct from approved oral treatments, which has drawn attention from investors focused on pulmonary medicine. The company is publicly traded and its progress through clinical trials is a key driver for its valuation.
52W Range: $22.24-$40.17
Congressional Interest in Avalyn Pharma Inc. (AVLN)
No congressional trades have been disclosed for Avalyn Pharma Inc. (AVLN) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
0
Unique Politicians
0
Buys
0
Sells
0
Who in Congress Is Trading AVLN?
No congressional trades found for this stock.